Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Shanghai Jiao Tong University

Status and phase

Enrolling

Phase 2

Conditions

Acute Lymphoblastic Leukemia

Treatments

Biological: single dose of Inaticabtagene autoleucel

Study type

Interventional

Funder types

Other

Identifiers

NCT06718244

(2024) Ruijin Ethics No.447

Details and patient eligibility

About

This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are in first complete remission(CR1) with minimal residual disease (MRD) positivity. This trial will enroll 20 participants for leukapheresis and treatment with lymphodepleting chemotherapy followed by Inati-cel CAR T cell infusion. Patients will be assessed for MRD negativity rate(at months 1, 2, 3, and 6 after CAR-T transfusion), duration of MRD negativity, overall survival(OS), relapse-free survival(RFS), pharmacokinetics(PK) characteristics, incidence of adverse events(AEs), exploratory biomarker research at 1,2,3,6,9,12,15,18,21 and 24- months post Inati-cel infusion.

Enrollment

20 estimated patients

Sex

All

Ages

16 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age between ≥16 and ≤70 years at screening, no gender restrictions
ECOG score of 0-1 at screening
Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy.
Newly diagnosed Ph-positive B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry or BCR-ABL1 >0.01% detected by qPCR) in CR1 (with <5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease) .
At diagnosis of B-ALL,CD19 expression of leukemic cells is positive by flow cytometry in bone marrow or peripheral blood.
Appropirate organ function, meeting the following criteria:
1. Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
2. Alanine aminotransferase (ALT) ≤3 times ULN;
3. Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN);
4. Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula);
5. International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN;
6. Left ventricular ejection fraction (LVEF) ≥50%;
7. Minimum pulmonary reserve, with oxygen saturation >91% on room air;
Meets leukapheresis standard of the study center, with no contraindications for blood cell separation;
Voluntarily agrees to participate in this study and signs on the informed consent form(ICF).

Exclusion criteria

Received CAR-T cell therapy before screening;
Inherited bone marrow failure syndrome(IBMFS) or any other known bone marrow failure syndromes;
Active systemic autoimmune diseases requiring treatment;
Any of the following conditions:
1. HBsAg and/or HBeAg positive;
2. HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification;
3. HCV-Ab positive;
4. TP-Ab positive;
5. HIV antibody positive;
6. EBV-DNA or CMV-DNA levels above the lower limit of quantification;
Active infection at screening.
Any other malignancy within the past five years before screening, excluding cases where the patient has been disease-free for more than 5 years after curative treatment or has a low risk of relapse as assessed by the investigator;
Any of the following cardiac conditions:
1. NYHA Class III or IV congestive heart failure;
2. Severe arrhythmia requiring treatment;
3. Uncontrolled hypertension or pulmonary hypertension despite standard therapy;
4. Unstable angina;
5. Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion;
6. Clinically significant valvular disease;
7. Other cardiac conditions deemed unsuitable by the investigator;
History of epilepsy, cerebellar disease, or other active central nervous system disorders;
Uncontrolled diabetes;
History of symptomatic deep vein thrombosis or pulmonary embolism within six months before screening that is not well controlled;
History of hypersensitivity to any component of the investigational product.
Received a live vaccine within six weeks before screening;
Life expectancy of less than three months;
Participation in another interventional clinical trial and receiving investigational drugs within three months (for unapproved drugs) or within five half-lives (for approved drugs) before cell infusion, or plans to participate in another clinical trial or receive anti-cancer therapy outside the study protocol during the study period;
Other conditions deemed unsuitable for participation in this clinical trial by the investigator.